ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]

AI-generated source summary

ImmunityBio (IBRX) shows a bullish short-term and long-term outlook based on moving averages and MACD signals. Despite a recent sell-off in the broader market, the stock has exhibited strong upward momentum and positive investor sentiment. The company's financial performance, while having some negative aspects like a negative P/E ratio, is bolstered by significant new agreements and approvals. Technically, the stock is trading above key moving averages and has shown a strong rally since its pivot low on February 13, 2026. Future resistance is anticipated around $12.94, with support expected at $8.70. Given these factors, IBRX is considered a buy candidate.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   24 Feb 2026, 03:56 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:24 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:11 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:11 UTC

   All evaluable predictions in this case reached terminal outcomes.